DNA topoisomerases as anticancer drug targets.

[1]  Nicholas R. Cozzarelli,et al.  DNA topology and its biological effects , 1990 .

[2]  D. J. Bosman,et al.  Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. , 1989, Cancer research.

[3]  T. Chung,et al.  Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[5]  Y. Pommier,et al.  Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.

[6]  S. Kaufmann.  Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. , 1989, Cancer research.

[7]  G. Hofmann,et al.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. , 1989, Biochemistry.

[8]  K. Kohn,et al.  Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.

[9]  A. Jacquemin-Sablon,et al.  Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. , 1989, Cancer research.

[10]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[11]  J. Hwang,et al.  Phorbol ester transiently increases topoisomerase I mRNA levels in human skin fibroblasts. , 1989, The Journal of biological chemistry.

[12]  L. Liu,et al.  Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. , 1989, Molecular pharmacology.

[13]  L. Liu,et al.  DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. , 1989, Cancer research.

[14]  L. Liu,et al.  Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. , 1989, The Journal of biological chemistry.

[15]  D. Figgitt,et al.  Topoisomerase II: a potential target for novel antifungal agents. , 1989, Biochemical and biophysical research communications.

[16]  R. Ralph,et al.  A protein factor that enhances amsacrine-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei. , 1989, Biochimica et biophysica acta.

[17]  N. Hanna,et al.  Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity. , 1989, Cancer research.

[18]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[19]  F. Palitti,et al.  Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. , 1989, Mutation research.

[20]  R. Hertzberg,et al.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. , 1989, Journal of medicinal chemistry.

[21]  E. Huberman,et al.  Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity. , 1989, Cancer research.

[22]  J. Hwang,et al.  Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. , 1989, Cancer research.

[23]  P. Lawson,et al.  Inhibition of protein synthesis reduces the cytotoxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line. , 1989, Biochemical pharmacology.

[24]  Y. Tsao,et al.  Transcription-driven supercoiling of DNA: Direct biochemical evidence from in vitro studies , 1989, Cell.

[25]  D. Botstein,et al.  DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage , 1989, Molecular and cellular biology.

[26]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[27]  G. Goldenberg,et al.  Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. , 1989, Cancer research.

[28]  G. Giaever,et al.  Supercoiling of intracellular DNA can occur in eukaryotic cells , 1988, Cell.

[29]  J. Wang,et al.  Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Almouzni,et al.  Assembly of spaced chromatin involvement of ATP and DNA topoisomerase activity. , 1988, The EMBO journal.

[31]  A. Fornace,et al.  DNA damage-inducible transcripts in mammalian cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Sternglanz,et al.  Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. , 1988, Molecular pharmacology.

[33]  T. Yoshinari,et al.  Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. , 1988, Biochemical and biophysical research communications.

[34]  D. Suttle,et al.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. , 1988, Biochemistry.

[35]  U. Strausfeld,et al.  Effects of VM26, a specific inhibitor of type II DNA topoisomerase, on SV40 chromatin replication in vitro. , 1988, Nucleic Acids Research.

[36]  P. Lawson,et al.  Relationship between sensitivity to 4'-(9-acridinylamino)methanesulfon-m-anisidide and DNA topoisomerase II in a cold-sensitive cell-cycle mutant of a murine mastocytoma cell line. , 1988, Biochimica et biophysica acta.

[37]  M. Muller,et al.  Single-strand DNA cleavages by eukaryotic topoisomerase II. , 1988, Biochemistry.

[38]  A. Bodley,et al.  Topoisomerases as Novel Targets for Cancer Chemotherapy , 1988, Bio/Technology.

[39]  J. Wang,et al.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Wang,et al.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[41]  N. Osheroff,et al.  Phosphorylation of DNA topoisomerase II in vivo and in total homogenates of Drosophila Kc cells. The role of casein kinase II. , 1988, The Journal of biological chemistry.

[42]  E. Di Mauro,et al.  Eukaryotic DNA topoisomerase I reaction is topology dependent. , 1988, Nucleic acids research.

[43]  F. Traganos,et al.  Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. , 1988, Cancer research.

[44]  A. Jacquemin-Sablon,et al.  Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells. , 1988, Biochemical pharmacology.

[45]  L. Liu,et al.  Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. , 1988, Cancer research.

[46]  Leroy F. Liu,et al.  Transcription generates positively and negatively supercoiled domains in the template , 1988, Cell.

[47]  G. Palù,et al.  Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid. , 1988, Biochemical pharmacology.

[48]  W. Earnshaw,et al.  cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[49]  L. Liu,et al.  Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[51]  R. Ralph,et al.  Mechanism of resistance of non-cycling mammalian cells to 4'-[9-acridinylamino]methanesulphon-m-anisidide: role of DNA topoisomerase II in log- and plateau-phase CHO cells. , 1988, Biochimica et biophysica acta.

[52]  W. Ross,et al.  Abrogation of etoposide-mediated cytotoxicity by cycloheximide. , 1988, Biochemical pharmacology.

[53]  R. Epstein.  TOPOISOMERASES IN HUMAN DISEASE , 1988, The Lancet.

[54]  V. Culotta,et al.  Sites of topoisomerase I action on X. laevis ribosomal chromatin: Transcriptionally active rDNA has an ∼200 bp repeating structure , 1988, Cell.

[55]  Y. Pommier,et al.  Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. , 1988, Cancer research.

[56]  W. Earnshaw,et al.  Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Wang,et al.  Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Gavin,et al.  Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures. , 1988, Cancer research.

[59]  C. Jaxel,et al.  Topoisomerase inhibitors induce irreversible fragmentation of replicated DNA in concanavalin A stimulated splenocytes. , 1988, Biochemistry.

[60]  Jb Davis.  Integration and control of metabolic processes: pure and applied aspects: Edited by O L Kon et al. pp 595. ISCU Press, Cambridge, UK. 1987 ISBN 0-521-34273-2 , 1988 .

[61]  A. Bodley,et al.  18 – Roles of DNA Topoisomerases in Drug Cytotoxicity and Drug Resistance , 1988 .

[62]  C. Cheng,et al.  Structural aspects of antineoplastic agents--a new approach. , 1988, Progress in medicinal chemistry.

[63]  T. Uemura,et al.  Cloning and sequencing of Schizosaccharomyces pombe DNA topoisomerase I gene, and effect of gene disruption. , 1987, Nucleic acids research.

[64]  D. Sullivan,et al.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. , 1987, The Journal of biological chemistry.

[65]  A. Wyllie,et al.  Apoptosis: Cell death in tissue regulation , 1987, The Journal of pathology.

[66]  E. Egyházi,et al.  Microinjection of anti-topoisomerase I immunoglobulin G into nuclei of Chironomus tentans salivary gland cells leads to blockage of transcription elongation , 1987, Molecular and cellular biology.

[67]  R. Lock,et al.  DNA topoisomerases in cancer therapy. , 1987, Anti-cancer drug design.

[68]  J. Wang,et al.  Supercoiling of the DNA template during transcription. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[69]  G. Schütz,et al.  Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene , 1987, Cell.

[70]  T. Uemura,et al.  DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe , 1987, Cell.

[71]  W. Ross,et al.  Topoisomerase-specific drug sensitivity in relation to cell cycle progression , 1987, Molecular and cellular biology.

[72]  D. S. Coffey,et al.  Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. , 1987, The Journal of urology.

[73]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[74]  D. Sullivan,et al.  Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. , 1987, Cancer research.

[75]  R. C. Adlakha,et al.  Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. , 1987, Biochemistry.

[76]  S. Crooke,et al.  Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. , 1987, Molecular pharmacology.

[77]  B. Thomsen,et al.  Preferential relaxation of supercoiled DNA containing a hexadecameric recognition sequence for topoisomerase I , 1987, Nature.

[78]  D. S. Coffey,et al.  Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. , 1987, Cancer research.

[79]  E. Estey,et al.  The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. , 1987, Biochemical and biophysical research communications.

[80]  M. Shibuya,et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. , 1987, The Journal of biological chemistry.

[81]  U. Strausfeld,et al.  Effects of VM26 (teniposide), a specific inhibitor of type II DNA topoisomerase, on SV40 DNA replication in vivo. , 1987, Nucleic acids research.

[82]  K. Kohn,et al.  Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. , 1987, Cancer research.

[83]  W. T. Beck,et al.  Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). , 1987, Cancer research.

[84]  L. Liu,et al.  Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Newport.  Nuclear reconstitution in vitro: Stages of assembly around protein-free DNA , 1987, Cell.

[86]  J. Newport,et al.  Disassembly of the nucleus in mitotic extracts: Membrane vesicularization, lamin disassembly, and chromosome condensation are independent processes , 1987, Cell.

[87]  S. Elgin,et al.  Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin , 1987, Molecular and cellular biology.

[88]  A. Bodley,et al.  Regulation of DNA topoisomerases during cellular differentiation. , 1987, NCI monographs : a publication of the National Cancer Institute.

[89]  D. Kroll,et al.  Camptothecin inhibits hsp 70 heat-shock transcription and induces DNA strand breaks in hsp 70 genes in Drosophila. , 1987, NCI monographs : a publication of the National Cancer Institute.

[90]  R. Sternglanz,et al.  Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA , 1987, Nature.

[91]  E. Estey,et al.  Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts. , 1987, Cancer research.

[92]  J. Riordan,et al.  The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. , 1986, Biochemical and biophysical research communications.

[93]  C. Larsen,et al.  Characterization of the topoisomerase II-induced cleavage sites in the c-myc proto-oncogene. In vitro stimulation by the antitumoral intercalating drug mAMSA. , 1986, Biochemical pharmacology.

[94]  R. Snapka.  Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication. , 1986, Molecular and cellular biology.

[95]  W. Earnshaw,et al.  Topoisomerase II: A specific marker for cell proliferation , 1986, The Journal of cell biology.

[96]  G. Riou,et al.  ATP-independent type II topoisomerase from trypanosomes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[97]  A. Udvardy,et al.  Topoisomerase II cleavage in chromatin. , 1986, Journal of molecular biology.

[98]  A. Montecucco,et al.  DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs. , 1986, Anticancer research.

[99]  A. Nordheim,et al.  DNA topoisomerase II cleaves at specific sites in the 5′ flanking region of c‐fos proto‐oncogenes in vitro. , 1986, The EMBO journal.

[100]  M. Brattain,et al.  DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. , 1986, Cancer research.

[101]  D. Brutlag,et al.  Multiple forms and cellular localization of Drosophila DNA topoisomerase II. , 1986, The Journal of biological chemistry.

[102]  Y. Pommier,et al.  Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. , 1986, Cancer research.

[103]  C. Larsen,et al.  In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene. , 1986, Biochemical and biophysical research communications.

[104]  T. Uemura,et al.  Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis , 1986, The EMBO journal.

[105]  D. Sullivan,et al.  Proliferation dependence of topoisomerase II mediated drug action. , 1986, Biochemistry.

[106]  U. K. Laemmli,et al.  Metaphase chromosome structure. Involvement of topoisomerase II. , 1986, Journal of molecular biology.

[107]  J. Wang,et al.  In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin , 1986, Molecular and cellular biology.

[108]  A. Wyllie,et al.  Death and the cell. , 1986, Immunology today.

[109]  W. Ross,et al.  Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. , 1986, Cancer research.

[110]  L. Liu,et al.  DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. , 1986, Cancer research.

[111]  W. Ross,et al.  Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. , 1986, Cancer research.

[112]  P. Cuatrecasas,et al.  Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[113]  John T. Lis,et al.  Topoisomerase I interacts with transcribed regions in Drosophila cells , 1986, Cell.

[114]  K. Kohn,et al.  Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. , 1986, Biochemistry.

[115]  D. Blangy,et al.  In vitro transcription by Xenopus oocytes RNA polymerase III requires a DNA topoisomerase II activity. , 1986, The EMBO journal.

[116]  Leroy F. Liu,et al.  Chapter 24. DNA Topoisomerases as Therapeutic Targets in Cancer Chemotherapy , 1986 .

[117]  H. Ikeda.  Illegitimate recombination: role of type II DNA topoisomerase. , 1986, Advances in biophysics.

[118]  W. Ross.  DNA topoisomerases as targets for cancer therapy. , 1985, Biochemical pharmacology.

[119]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[120]  M. Goodenough,et al.  Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells. , 1985, The EMBO journal.

[121]  L. Liu,et al.  Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. , 1985, Cancer research.

[122]  J. Jongstra-Bilen,et al.  Inhibition of calf thymus type II DNA topoisomerase by poly(ADP‐ribosylation). , 1985, The EMBO journal.

[123]  Y. Pommier,et al.  Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. , 1985, Cancer research.

[124]  R. Ralph,et al.  Chromosomol DNA fragments from mouse cells exposed to an intercalating agent contain a 175-kdalton terminal polypeptide. , 1985, Canadian journal of biochemistry and cell biology = Revue canadienne de biochimie et biologie cellulaire.

[125]  M. Brattain,et al.  Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. , 1985, Cancer research.

[126]  N. Osheroff,et al.  In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[127]  D. Botstein,et al.  DNA topoisomerase II is required at the time of mitosis in yeast , 1985, Cell.

[128]  M. Muller,et al.  Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. , 1985, The EMBO journal.

[129]  N. Osheroff,et al.  Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[130]  W. Earnshaw,et al.  Topoisomerase II is a structural component of mitotic chromosome scaffolds , 1985, The Journal of cell biology.

[131]  M. Fukada.  Action of camptothecin and its derivatives on deoxyribonucleic acid. , 1985, Biochemical pharmacology.

[132]  A. Udvardy,et al.  Novel partitioning of DNA cleavage sites for Drosophila topoisomerase II , 1985, Cell.

[133]  L. Liu,et al.  Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. , 1985, The Journal of biological chemistry.

[134]  H. Vosberg.  DNA topoisomerases: enzymes that control DNA conformation. , 1985, Current topics in microbiology and immunology.

[135]  J. Riordan,et al.  Genetic and biochemical characterization of multidrug resistance. , 1985, Pharmacology & therapeutics.

[136]  R. Ralph,et al.  The mechanism of action of mAMSA. , 1985, Advances in cancer research.

[137]  L. Liu,et al.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.

[138]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[139]  J. Wang,et al.  Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[140]  M. Duguet,et al.  DNA topoisomerase activities in concanavalin A‐stimulated lymphocytes , 1984, FEBS letters.

[141]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[142]  H. Vosberg,et al.  Characterisation of size variants of type I DNA topoisomerase isolated from calf thymus. , 1984, European journal of biochemistry.

[143]  J. Wang,et al.  The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae. , 1984, The Journal of biological chemistry.

[144]  T. Uemura,et al.  Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. , 1984, The EMBO journal.

[145]  F. Castora,et al.  Isolation of a mitochondrial DNA topoisomerase from human leukemia cells. , 1984, Biochemical and biophysical research communications.

[146]  R. Sternglanz,et al.  DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[147]  M. Brattain,et al.  Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. , 1984, Biochemistry.

[148]  L. Liu,et al.  Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[149]  B. Olivera,et al.  Poly(ADP-ribosylation) of DNA topoisomerase I from calf thymus. , 1984, The Journal of biological chemistry.

[150]  Y. Tse‐Dinh,et al.  Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro , 1984, Nature.

[151]  L. Liu,et al.  Cleavage of DNA by mammalian DNA topoisomerase II. , 1983, The Journal of biological chemistry.

[152]  P. Mandel,et al.  DNA topoisomerase I from calf thymus is inhibited in vitro by poly(ADP-ribosylation). , 1983, European journal of biochemistry.

[153]  M. Waring,et al.  Molecular Aspects of Anti-Cancer Drug Action , 1983 .

[154]  R. Ralph,et al.  Blocked 5'-termini in the fragments of chromosomal DNA produced in cells exposed to the antitumor drug 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide (mAMSA). , 1983, Nucleic acids research.

[155]  R. Ralph,et al.  Anti-cancer drugs which intercalate into DNA: How do they act? , 1983 .

[156]  H. Bernstein,et al.  Epidermal growth factor-induced topoisomerase(s). Intracellular translocation and relation to DNA synthesis. , 1983, Experimental cell research.

[157]  B. Olivera,et al.  Poly(ADP-ribosylation) of a DNA topoisomerase. , 1983, The Journal of biological chemistry.

[158]  M. Muller,et al.  Biochemical characterization of topoisomerase I purified from avian erythrocytes. , 1983, Nucleic acids research.

[159]  W. Zimmermann,et al.  Characterization of a prokaryotic topoisomerase I activity in chloroplast extracts from spinach. , 1983, Nucleic Acids Research.

[160]  M. Duguet,et al.  DNA topoisomerases from rat liver: physiological variations. , 1983, Nucleic acids research.

[161]  R. Gupta,et al.  Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. , 1983, Cancer research.

[162]  Leroy F. Liu.  [7] HeLa toposiomerase I , 1983 .

[163]  T. Hsieh.  Purification and properties of type II DNA topoisomerase from embryos of Drosophila melanogaster. , 1983, Methods in enzymology.

[164]  L. Liu,et al.  DNA topoisomerases--enzymes that catalyse the breaking and rejoining of DNA. , 1983, CRC critical reviews in biochemistry.

[165]  A. Wozniak,et al.  DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. , 1983, Cancer research.

[166]  K. Kohn,et al.  Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. , 1982, Biochemical pharmacology.

[167]  B. Baguley,et al.  Comparison of the in vivo and in vitro antileukemic activity of monosubstituted derivatives of 4'-(9-acridinylamino)methanesulfon-m-anisidide. , 1982, Molecular pharmacology.

[168]  R. Ralph,et al.  A simple method for detecting drug effects on the DNA of mammalian cells. , 1982, Analytical biochemistry.

[169]  R. Ralph,et al.  The nature of DNA breakage by 4'‐[(9‐acridinyl)amino]methane‐sulphon‐m‐anisidide , 1982, FEBS letters.

[170]  L. Zwelling,et al.  Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with adriamycin and 4'-(9-acridinylamino)methanesulfon-m-anisidide. , 1982, Cancer research.

[171]  R. Ralph,et al.  A reassessment of the mechanism of action of 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide. , 1982, European journal of cancer & clinical oncology.

[172]  W. Ross,et al.  Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. , 1982, Biochemical pharmacology.

[173]  L. Liu,et al.  Recognition sites of eukaryotic DNA topoisomerase I: DNA nucleotide sequencing analysis of topo I cleavage sites on SV40 DNA. , 1982, Nucleic acids research.

[174]  L. Liu,et al.  Intra- and intermolecular strand transfer by HeLa DNA topoisomerase I. , 1982, The Journal of biological chemistry.

[175]  H. Fukata,et al.  Isolation and partial characterization of two distinct DNA topoisomerases from cauliflower inflorescence. , 1982, Journal of biochemistry.

[176]  M. Ellison,et al.  Purification and properties of type 1 topoisomerase from chicken erythrocytes: mechanism of eukaryotic topoisomerase action. , 1982, Biochemistry.

[177]  B. Barlogie,et al.  Lethal activity and kinetic response of cultured human cells to 4'-(9-acridinylamino)methanesulfon-m-anisidine. , 1982, Cancer research.

[178]  K. Kohn,et al.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. , 1981, Biochemistry.

[179]  L. Liu,et al.  A homogeneous type II DNA topoisomerase from HeLa cell nuclei. , 1981, The Journal of biological chemistry.

[180]  M. Waring,et al.  Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. , 1981, Molecular pharmacology.

[181]  W. Wilson,et al.  Cell-cycle-stage specificity of 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and interaction with ionizing radiation in mammalian cell cultures. , 1981, Radiation research.

[182]  W. Ross,et al.  DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. , 1981, Biochimica et biophysica acta.

[183]  R. Burgess,et al.  Purification and characterization of wheat germ DNA topoisomerase I (nicking-closing enzyme). , 1981, The Journal of biological chemistry.

[184]  B. Baguley,et al.  Antitumour activity of substituted 9-anilinoacridines--comparison of in vivo and in vitro testing systems. , 1981, European journal of cancer.

[185]  L. Liu,et al.  Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[186]  J. Champoux,et al.  DNA breakage and closure by rat liver type 1 topoisomerase: separation of the half-reactions by using a single-stranded DNA substrate. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[187]  W. Denny,et al.  Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues. , 1981, Journal of medicinal chemistry.

[188]  M. Waring,et al.  DNA modification and cancer. , 1981, Annual review of biochemistry.

[189]  D. Brutlag,et al.  ATP-dependent DNA topoisomerase from D. melanogaster reversibly catenates duplex DNA rings , 1980, Cell.

[190]  Chung-Cheng Liu,et al.  Type II DNA topoisomerases: Enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break , 1980, Cell.

[191]  N. Cozzarelli.  DNA gyrase and the supercoiling of DNA. , 1980, Science.

[192]  M. Gellert,et al.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[193]  P. Brown,et al.  A topoisomerase from Escherichia coli related to DNA gyrase. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[194]  K. Kohn,et al.  Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. , 1979, Biochimica et biophysica acta.

[195]  W. Denny,et al.  Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity. , 1979, Journal of medicinal chemistry.

[196]  Leroy F. Liu,et al.  Chapter II – DNA Topoisomerases: Enzymes That Catalyze the Concerted Breaking and Rejoining of DNA Backbone Bonds , 1979 .

[197]  K W Kohn,et al.  Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. , 1978, Biochimica et biophysica acta.

[198]  T. Brown,et al.  Induction of limited DNA damage by the antitumor agent Cain's acridine. , 1978, Cancer research.

[199]  J. Wang,et al.  Micrococcus luteus DNA gyrase: active components and a model for its supercoiling of DNA. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[200]  J. Champoux.  Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[201]  J. Loike,et al.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. , 1976, Biochemistry.

[202]  M. Gellert,et al.  DNA gyrase: an enzyme that introduces superhelical turns into DNA. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[203]  J. Champoux,et al.  Purification and characterization of the DNA untwisting enzyme from rat liver. , 1976, Biochemistry.

[204]  G. Atwell,et al.  Potential antitumor agents. 19. Multiply substituted 4'-(9-acridinylamino)methanesulfonanilides. , 1976, Journal of medicinal chemistry.

[205]  G. Atwell,et al.  The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. , 1974, European journal of cancer.

[206]  G. Neil,et al.  The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors. , 1973, Cancer research.

[207]  S. Kuentzel,et al.  Cell-kill kinetics of several S-phase-specific drugs. , 1973, Cancer research.

[208]  L. Li,et al.  Action of camptothecin on mammalian cells in culture. , 1972, Cancer research.

[209]  D. Kessel,et al.  Studies on camptothecin-induced degradation and apparent reaggregation of DNA from L1210 cells. , 1972, Biochemical and biophysical research communications.

[210]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[211]  D. Kessel,et al.  Camptothecin effects on DNA synthesis in murine leukemia cells. , 1972, Biochimica et biophysica acta.

[212]  Gottlieb Ja,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972 .

[213]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[214]  M. Horwitz,et al.  Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. , 1971, Biochemical and biophysical research communications.

[215]  A. Grollman,et al.  Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. , 1971, Molecular pharmacology.

[216]  D. Kessel,et al.  Effects of camptothecin on RNA synthesis in leukemia L1210 cells. , 1971, Biochimica et biophysica acta.

[217]  R. Adamson,et al.  Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. , 1971, Journal of the National Cancer Institute.

[218]  G. Atwell,et al.  Potential antitumour agents. 11. 9-anilinoacridines. , 1971, Journal of medicinal chemistry.

[219]  H. Bosmann,et al.  Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria of E. coli. , 1970, Biochemical and biophysical research communications.

[220]  E. Carlinfanti,et al.  Use of a tourniquet to prolong the effect of penicillin. , 1947, Lancet.